• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Clearside Biomedical

Regenxbio pulls trigger on option to license Clearside Biomedical’s SCS Microinjector

October 31, 2019 By Sean Whooley

Clearside Biomedical (NSDQ:CLSD) said yesterday that Regenxbio (NSDQ:RGNX) exercised its option to license Clearside’s in-office SCS Microinjector for delivering adeno-associated virus (AAV)-based therapeutics in treating wet age-related macular degeneration, diabetic retinopathy and other conditions. The two companies inked the option and licensing deal that they said at the time could be worth more than $130 million on […]

Filed Under: Business/Financial News, Drug-Device Combinations, Optical/Ophthalmic Tagged With: Clearside Biomedical, regenxbio

Clearside Biomedical inks $76m licensing deal with Bausch for Xipere

October 23, 2019 By Sean Whooley

Clearside Biomedical (NSDQ:CLSD) said yesterday that it entered into a license agreement with Bausch Health Ireland (NYSE:BHC) worth up to $76 million for the Xipere device for the treatment of macular edema associated with uveitis. The agreement grants Bausch an exclusive license to develop, manufacture, distribute, promote, market and commercialize the suprachoroidal injection device. Get the full […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceutical Tagged With: bauschhealth, Clearside Biomedical, FDA

Clearside Biomedical confirms timeline for Xipere

October 21, 2019 By Sean Whooley

Clearside Biomedical (NSDQ:CLSD) last week said that the FDA found no efficacy issues with its Xipere drug-delivery technology and will not ask for further clinical efficacy studies. The Xipere device is a suprachoroidal injection designed for the treatment of macular edema associated with uveitis. In October 2018, Clearside touted data from a Phase III pivotal trial, which reported […]

Filed Under: Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceutical Tagged With: Clearside Biomedical, FDA

Clearside Biomedical, Regenxbio ink sales deal for gene therapy microinjector

September 5, 2019 By Nancy Crotti

Clearside Biomedical (NSDQ:CLSD) has agreed to grant Regenxbio (NSDQ:RGNX) the option to an exclusive worldwide license to sell Clearside’s SCS gene therapy microinjector. The option and licensing deal is potentially worth more than $130 million, the companies said. Get the full story on our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Clearside Biomedical, regenxbio

FDA wants more on new manufacturing process from Clearside Biomedical

August 22, 2019 By Sean Whooley

Clearside Biomedical (NSDQ:CLSD) said today that the FDA ordered the company to provide stability data on its new manufacturing process for triamcinolone acetonide suspension, pushing the timeline on the agency’s decision into next year. Alpharetta, Ga.-based Clearside’s Xipere device is a suprachoroidal injection designed for the treatment of macular edema associated with uveitis. Clearside said the […]

Filed Under: Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceutical Tagged With: Clearside Biomedical

Clearside Biomedical licenses microinjector to Aura Biosciences

July 9, 2019 By Brad Perriello

Clearside Biomedical (NSDQ:CLSD) said today that it licensed its microinjector technology to Aura Biosciences for use with Aura drug candidates in treating ocular cancers. Alpharetta, Ga.-based Clearside’s Suprachoroidal Space Microinjector is designed to deliver therapeutics into the suprachoroidal space between the sclera and choroid of the eye. Aura, based in Cambridge, Mass., is developing viral nanoparticle […]

Filed Under: Drug-Device Combinations, Optical/Ophthalmic, Research & Development Tagged With: Aura Biosciences, Clearside Biomedical

Medtronic taps Lennon as CIO | Personnel Moves – April 9, 2018

April 9, 2019 By Fink Densford

Medtronic (NYSE:MDT) said that it named Sean Lennon as its new chief information officer, set to take effect April 29. The Fridley, Minn.-based medtech giant said that Lennon will take over for Mike Hedges, who is retiring from the position after 19 years with Medtronic, including 10 as CIO. Prior to joining Medtronic, Lennon served as […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: Allergan, Clearside Biomedical, ICU Medical Inc., iHear Medical, LifeScan Inc., lumenxt, Medtronic, Novartis, OptiScan, oregonbioscienceassociation, Owens and Minor, Shape Memory Therapeutics, SynCardia

Clearside Biomedical shares down on Q4 miss

March 13, 2019 By Fink Densford

Shares in Clearside Biomedical (NSDQ:CLSD) have fallen slightly today after the biopharmaceutical company posted fourth quarter 2018 earnings that missed expectations on Wall Street. The Alpharetta, Ga.-based company reported research and development costs of approximately $17.5 million with a total net loss of $21.6 million, or 68¢ per share, for the three months ended December 31, […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Clearside Biomedical

Google taps ex-Geisinger CEO Feinberg to lead consolidated Google Health biz | Personnel Moves – November 14, 2018

November 14, 2018 By Fink Densford

Google (NSDQ:GOOG) has picked up former Geisinger Health CEO David Feinberg to lead its fragmented health divisions under the Google Health moniker, according to a recent CNBC report. The tech giant had been searching for a head for several months, with artificial intelligence head Jeff Dean heavily involved in the process, according to the report. Other […]

Filed Under: Business/Financial News, Featured Tagged With: Accuray Inc., Alphabet (Google), BioCardia, Bovie Medical Corp., Clearside Biomedical, Eos Imaging, Geisinger Health System, Getinge, hancockjaffelabs, Intact Vascular, Integra LifeSciences, Intuitive Surgical, mperiatherapeutics, Owens and Minor, Procept BioRobotics, Profound Medical Inc., Verily

Clearside Biomedical reports analyses from pivotal trial of eye drug

October 29, 2018 By Sarah Faulkner

Clearside Biomedical (NSDQ:CLSD) touted new analyses of data from the company’s Phase III pivotal trial of suprachoroidal CLS-TA in people with uveitic macular edema. The company’s investigational treatment is a suspension of triamcinolone acetonide formulated to be delivered to the back of the eye via the suprachoroidal space. Get the full story at our sister site, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Clearside Biomedical

Philips board backs reappointment of CEO van Houten, CFO Bhattacharya | Personnel Moves – October 29, 2018

October 29, 2018 By Fink Densford

Royal Philips (NYSE:PHG) said today that its board of directors is backing the re-appointment of Frans van Houten as its president and CEO and Abhijit Bhattacharya as chief financial officer and board member. CEO van Houten has been at the head of Philips since 2011, while Bhattacharya joined the company in 2015, Amsterdam-based Philips said. During […]

Filed Under: Business/Financial News, Featured Tagged With: aligntechnology, Bovie Medical Corp., Clearside Biomedical, cromsource, Fisher & Paykel Healthcare, Harvard Bioscience Inc., Philips, Ra Medical, RenovaCare, Sight Sciences

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS